pmid	doi	year	title	Hugo_Symbol
33735152	10.1097/MPH.0000000000002140	2022	Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort.	BCR
33769465	10.5858/arpa.2020-0454-OA	2022	One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.	BCR
33780164	10.1002/cyto.b.22002	2022	Lymphoid blasts with aberrant myeloid marker expression and BCR/ABL1: Is it mixed phenotype acute leukemia or B lymphoblastic leukemia?	BCR
34193976	10.1038/s41375-021-01326-x	2022	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	BCR
34379028	10.1080/10428194.2021.1961234	2022	Early prediction of stable MR<sup>4.5</sup> by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.	BCR
34462243	10.1016/j.clml.2021.07.001	2022	Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors.	BCR
34486918	10.1080/10428194.2021.1975191	2022	Chronic myeloid leukemia with pure erythroid leukemia blast crisis.	BCR
34493150	10.1080/10428194.2021.1971219	2022	Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.	BCR
34561201	10.1016/j.clml.2021.08.003	2022	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.	BCR
34582325	10.1080/08880018.2021.1966558	2022	Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.	BCR
34587720	10.3324/haematol.2021.279125	2022	Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin.	BCR
34617186	10.1007/s12185-021-03231-6	2022	Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.	BCR
34617433	10.4274/tjh.galenos.2021.2021.0326	2022	Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients	BCR
34624079	10.1182/blood.2021012081	2022	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.	BCR
34657128	10.1038/s41375-021-01448-2	2022	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.	BCR
34662891	10.1182/bloodadvances.2021005245	2022	VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group.	BCR
34676543	10.1111/bjh.17869	2022	Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.	BCR
34711926	10.1038/s41375-021-01455-3	2022	Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.	BCR
34758608	10.3324/haematol.2021.279807	2022	Detection of <i>ABL1</i> kinase domain mutations in therapy-naïve <i>BCR-ABL1</i>-positive acute lymphoblastic leukemia.	BCR
34775888	10.1080/10428194.2021.2002320	2022	Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.	BCR
34783280	10.1080/10428194.2021.1999439	2022	PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of <i>BCR-ABL1</i>-like acute lymphoblastic leukaemia in Indian patients.	BCR
34788984	10.3324/haematol.2021.279177	2022	Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.	BCR
34795418	10.1038/s41375-021-01470-4	2022	Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.	BCR
34816424	10.1111/bjh.17966	2022	Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.	BCR
34818644	10.1159/000519782	2022	BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.	BCR
34854546	10.1002/pbc.29441	2022	Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.	BCR
34866312	10.1002/pbc.29490	2022	Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.	BCR
34872441	10.1080/10428194.2021.2010059	2022	<i>SOCS-2</i> gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.	BCR
34874488	10.1007/s11596-021-2477-0	2022	Cytogenetic Characteristics of Childhood Acute Lymphoblastic Leukemia: A Study of 1541 Chinese Patients Newly Diagnosed between 2001 and 2014.	BCR
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	BCR
34902205	10.1111/cas.15239	2022	RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.	BCR
34903489	10.1016/j.clml.2021.11.007	2022	State-of-the-Art Review on Myelofibrosis Therapies.	BCR
34930078	10.1080/10428194.2021.2015590	2022	Prediction for sustained deep molecular response for treatment-free remission.	BCR
34933827	10.1016/j.clml.2021.11.012	2022	The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.	BCR
34952433	10.1016/j.ejmech.2021.114051	2022	Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).	BCR
34987015	10.1016/j.clml.2021.12.007	2022	'FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre'.	BCR
34991679	10.1186/s13045-021-01221-z	2022	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.	BCR
35011712	10.3390/cells11010150	2022	The Molecular Subtype of Adult Acute Lymphoblastic Leukemia Samples Determines the Engraftment Site and Proliferation Kinetics in Patient-Derived Xenograft Models.	BCR
35022343	10.2169/internalmedicine.8392-21	2022	Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose.	BCR
35027410	10.1158/1078-0432.CCR-21-3959	2022	Progress in Transplants for Acute Lymphoblastic Leukemia.	BCR
35051110	10.3390/vetsci9010026	2022	Feline and Canine Cutaneous Lymphocytosis: Reactive Process or Indolent Neoplastic Disease?	BCR
35061886	10.1182/bloodadvances.2021006076	2022	SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.	BCR
35075985	10.1080/10428194.2021.2018582	2022	Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.	BCR
35077445	10.1371/journal.pone.0261469	2022	T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival.	BCR
35082399	10.1038/s41417-021-00415-4	2022	CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.	BCR
35084434	10.1001/jamaoncol.2021.6826	2022	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.	BCR
35119131	10.1002/ajh.26487	2022	Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping.	BCR
35121370	10.1016/j.ejca.2021.12.029	2022	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.	BCR
35123463	10.1186/s12920-022-01169-0	2022	A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript.	BCR
35126963	10.1177/20406207211072839	2022	MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.	BCR
35142153	10.3324/haematol.2021.280433	2022	Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin.	BCR
35158410	10.1111/ejh.13755	2022	Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.	BCR
35165777	10.1007/s00277-022-04791-1	2022	A case report of BCR-ABL1 rearrangement in de novo adult T-cell lymphoblastic leukemia/lymphoma with normal karyotype.	BCR
35171727	10.1080/10428194.2022.2025797	2022	MUC4 expression by immunohistochemistry is a specific marker for <i>BCR-ABL1+</i> and <i>BCR-ABL1</i>-like B-lymphoblastic leukemia.	BCR
35181934	10.1111/vcp.13062	2022	A challenging case of lymphoproliferative disease in a cat.	BCR
35195876	10.1007/s40265-022-01680-9	2022	Olverembatinib: First Approval.	BCR
35205606	10.3390/cancers14040860	2022	Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.	BCR
35205731	10.3390/cancers14040983	2022	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart.	BCR
35210562	10.1038/s41409-022-01618-5	2022	Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study.	BCR
35218741	10.1016/j.bcp.2022.114977	2022	Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.	BCR
35230873	10.1126/scisignal.abk3083	2022	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	BCR
35255496	10.1182/bloodadvances.2021006147	2022	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	BCR
35256549	10.5045/br.2021.2021198	2022	Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia.	BCR
35257981	10.1016/j.drup.2022.100822	2022	Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma.	BCR
35259456	10.1016/j.cellsig.2022.110301	2022	Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).	BCR
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	BCR
35267003	10.1182/blood.2021014726	2022	Pseudo-Chédiak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement.	BCR
35275990	10.1182/blood.2021015341	2022	Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.	BCR
35290157	10.1080/10428194.2022.2047673	2022	Significance of <i>RUNX1</i> mutation in <i>BCR-ABL1</i> positive acute myeloid leukemia - a diagnostic dilemma in a young woman with persistent bleeding.	BCR
35295854	10.3389/fcell.2022.838871	2022	Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells.	BCR
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	BCR
35306137	10.1016/j.cellsig.2022.110311	2022	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	BCR
35319509	10.1097/MPH.0000000000002271	2022	Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance.	BCR
35337248	10.1080/10428194.2022.2056180	2022	Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients.	BCR
35344115	10.1007/s11033-022-07337-w	2022	Identification and validation of suitable housekeeping genes for gene expression studies in BCR-ABL1 positive B-lineage acute lymphoblastic leukemia.	BCR
35349077	10.1007/s12185-022-03329-5	2022	Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group.	BCR
35350909	10.1177/10781552221090869	2022	Real-world management of targeted therapies in chronic lymphocytic leukemia.	BCR
35358441	10.1016/S2352-3026(22)00038-2	2022	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.	BCR
35358442	10.1016/S2352-3026(22)00036-9	2022	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.	BCR
35359041	10.3760/cma.j.cn112151-20211028-00781	2022	[Characteristics of fusion gene expression in acute lymphoblastic leukemia].	BCR
35361036	10.1080/10428194.2022.2045599	2022	Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.	BCR
35389507	10.1111/bjh.18175	2022	Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.	BCR
35398488	10.1016/j.cellsig.2022.110331	2022	SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.	BCR
35398858	10.1097/MPH.0000000000002456	2022	Mutational Analysis of the VPREB1 Gene of Pre-BCR Complex in a Cohort of Sporadic Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.	BCR
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	BCR
35416325	10.1002/hon.3004	2022	LncRNA FIRRE stimulates PTBP1-induced Smurf2 decay, stabilizes B-cell receptor, and promotes the development of diffuse large B-cell lymphoma.	BCR
35435617	10.1007/s11864-022-00953-5	2022	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	BCR
35440579	10.1038/s41467-022-29835-y	2022	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.	BCR
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	BCR
35472072	10.1371/journal.ppat.1010453	2022	Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.	BCR
35478711	10.2147/CMAR.S353022	2022	Primary Testicular and Cutaneous Philadelphia Chromosome Positive B-Cell Lymphoblastic Lymphoma: A Rare Case and Review.	BCR
35482146	10.1007/s11307-022-01733-1	2022	[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase.	BCR
35484080	10.1016/j.clml.2022.03.007	2022	Clinico-hematological and Outcome Profile of Pediatric B-other-ALL and BCR::ABL1-like pre-B-ALL: An Integrated Genomic Study From North India.	BCR
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	BCR
35486832	10.1182/blood.2021013990	2022	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.	BCR
35523687	10.1016/j.anpede.2021.02.016	2022	Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia.	BCR
35548364	10.3389/fphar.2022.834113	2022	Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.	BCR
35570070	10.1016/j.blre.2022.100969	2022	Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.	BCR
35574218	10.18632/oncotarget.28228	2022	Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation.	BCR
35577905	10.1038/s41375-022-01596-z	2022	Changing causes of death in persons with haematological cancers 1975-2016.	BCR
35588855	10.1016/j.ab.2022.114736	2022	Various types of electrochemical biosensors for leukemia detection and therapeutic approaches.	BCR
35597428	10.1016/j.cellsig.2022.110358	2022	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.	BCR
35597806	10.1038/s41375-022-01598-x	2022	Inability to phosphorylate Y88 of p27<sup>Kip1</sup> enforces reduced p27 protein levels and accelerates leukemia progression.	BCR
35611214	10.2147/IJN.S355408	2022	Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma.	BCR
35641210	10.1093/oncolo/oyab052	2022	Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.	BCR
35644195	10.7499/j.issn.1008-8830.2111108	2022	[Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the <i>PRAME</i> gene].	BCR
35650206	10.1038/s41467-022-30651-7	2022	Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.	BCR
35650277	10.1038/s41416-022-01806-6	2022	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.	BCR
35681213	10.1186/s13058-022-01536-w	2022	Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.	BCR
35745866	10.3390/pharmaceutics14061294	2022	Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.	BCR
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	BCR
35785180	10.3389/fonc.2022.901797	2022	Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.	BCR
35802654	10.1371/journal.pone.0270710	2022	Development and application of a next-generation sequencing protocol and bioinformatics pipeline for the comprehensive analysis of the canine immunoglobulin repertoire.	BCR
35804999	10.3390/cancers14133229	2022	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.	BCR
35842355	10.1016/j.clml.2022.05.002	2022	Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.	BCR
35884363	10.3390/cancers14143300	2022	Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.	BCR
35885931	10.3390/genes13071144	2022	Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.	BCR
35906470	10.1038/s41598-022-17271-3	2022	Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.	BCR
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	BCR
35920412	10.1002/jbt.23185	2022	Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro.	BCR
35922951	10.11406/rinketsu.63.799	2022	[Treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia in children].	BCR
35941532	10.1186/s10020-022-00518-0	2022	Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.	BCR
35953718	10.1038/s41591-022-01927-8	2022	Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.	BCR
35983732	10.1080/10428194.2022.2098291	2022	Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.	BCR
36011285	10.3390/genes13081374	2022	Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction.	BCR
36029036	10.1111/bjh.18418	2022	Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.	BCR
36035991	10.3389/fcell.2022.935023	2022	Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.	BCR
36051037	10.1002/jha2.475	2022	B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.	BCR
36057522	10.1016/j.clml.2022.07.014	2022	Treatment of Ph-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults with an Affordable Outpatient Pediatric Regimen.	BCR
36068158	10.1016/j.clml.2022.07.017	2022	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.	BCR
32068648	10.1097/MPH.0000000000001743	2021	B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.	BCR
32193251	10.3324/haematol.2019.242701	2021	The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.	BCR
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	BCR
32467145	10.3324/haematol.2020.247973	2021	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.	BCR
32581286	10.1038/s41409-020-0982-6	2021	Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.	BCR
32654389	10.1111/ajt.16194	2021	Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib.	BCR
32675219	10.3324/haematol.2020.252767	2021	Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice.	BCR
32675228	10.3324/haematol.2019.241653	2021	Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma.	BCR
32785655	10.1182/blood.2019004713	2021	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.	BCR
32799601	10.1080/10428194.2020.1808205	2021	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up.	BCR
32859541	10.1016/j.pedneo.2020.07.016	2021	Cytogenetic aberration in mixed-phenotype acute leukemia in children: A single-center retrospective review.	BCR
32871588	10.1182/blood.2020005514	2021	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.	BCR
32898857	10.1182/blood.2020005655	2021	Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.	BCR
32910713	10.1080/15548627.2020.1821546	2021	TFG is required for autophagy flux and to prevent endoplasmic reticulum stress in CH12 B lymphoma cells.	BCR
32915195	10.1093/carcin/bgaa095	2021	Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.	BCR
32919926	10.1016/j.clml.2020.08.006	2021	BCR-ABL1-Negative Chronic Myeloproliferative Neoplasms and Pulmonary Hypertension: A Prospective Long-Term Follow-up Study of the Impact of Pulmonary Hypertension on Survival.	BCR
32951102	10.1007/s12185-020-03006-5	2021	Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.	BCR
32954738	10.21037/apm-20-469	2021	Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.	BCR
32981690	10.1016/j.bulcan.2020.07.008	2021	[ALL in adult patients: Contribution and limits of pediatric management].	BCR
33021423	10.1080/10428194.2020.1827242	2021	Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.	BCR
33024996	10.1182/blood.2020004996	2021	Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.	BCR
33089525	10.1111/ejh.13538	2021	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.	BCR
33094664	10.1080/15476286.2020.1838783	2021	LncRNAs in adaptive immunity: role in physiological and pathological conditions.	BCR
33106061	10.1080/10428194.2020.1837366	2021	Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph<sup>+</sup> B cells but not bone marrow stem/progenitors.	BCR
33125593	10.1007/s00411-020-00879-2	2021	Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries.	BCR
33150806	10.1080/10428194.2020.1842397	2021	Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.	BCR
33153332	10.1080/10428194.2020.1839655	2021	Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.	BCR
33153355	10.1080/10428194.2020.1838509	2021	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.	BCR
33153366	10.1080/10428194.2020.1839649	2021	Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.	BCR
33161794	10.1080/10408363.2020.1829537	2021	The genomic and biological complexity of mixed phenotype acute leukemia.	BCR
33168949	10.1038/s41375-020-01082-4	2021	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.	BCR
33204013	10.1038/s41375-020-01090-4	2021	A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study.	BCR
33225446	10.1002/path.5592	2021	Classification of intestinal T-cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status.	BCR
33230570	10.1007/s00277-020-04354-2	2021	Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.	BCR
33238261	10.1159/000510112	2021	Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.	BCR
33251904	10.1080/10428194.2020.1849679	2021	The regulation of bcr-abl in hypoxia is through the mTOR pathway.	BCR
33272709	10.1016/j.bioorg.2020.104385	2021	Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.	BCR
33283555	10.1080/10428194.2020.1855340	2021	Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.	BCR
33283580	10.1080/10428194.2020.1849672	2021	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.	BCR
33284042	10.1080/10428194.2020.1856834	2021	Development of <i>BCR-ABL1</i>-positive ɤδ T-cell leukemia after treatment for thymoma type B1.	BCR
33303420	10.1016/j.clml.2020.10.009	2021	Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.	BCR
33303632	10.1074/jbc.RA120.015285	2021	A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.	BCR
33356699	10.1080/10428194.2020.1861274	2021	Evaluation of two CE-IVD tests for <i>BCR-ABL1</i> transcript monitoring of chronic myeloid leukemia patients.	BCR
33357483	10.1016/S2352-3026(20)30353-7	2021	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.	BCR
33357484	10.1016/S2352-3026(20)30362-8	2021	Are we ABL to do better for children with BCR-ABL1-like acute lymphocytic leukaemia?	BCR
33367563	10.1093/ajcp/aqaa244	2021	Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.	BCR
33373915	10.1016/j.biopha.2020.111166	2021	Yishen-tongbi decoction inhibits excessive activation of B cells by activating the FcγRIIb/Lyn/SHP-1 pathway and attenuates the inflammatory response in CIA rats.	BCR
33390067	10.1080/10428194.2020.1861275	2021	<i>In-vitro</i> modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene <i>RANBP2-ABL1</i> - implications for targeted therapy.	BCR
33403687	10.1111/bjh.17301	2021	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.	BCR
33414171	10.1158/0008-5472.CAN-20-1504	2021	CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.	BCR
33416167	10.3892/or.2020.7888	2021	Involvement of Blnk and Foxo1 in tumor suppression in BCR‑ABL1‑transformed pro‑B cells.	BCR
33419778	10.1158/1078-0432.CCR-20-3741	2021	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.	BCR
33427570	10.1080/10428194.2020.1864352	2021	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.	BCR
33428808	10.1111/cas.14808	2021	Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan.	BCR
33432783	10.1111/ijlh.13456	2021	Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.	BCR
33435587	10.3390/ijms22020592	2021	Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.	BCR
33443592	10.1007/s00277-021-04412-3	2021	Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.	BCR
33477957	10.3390/cancers13020354	2021	Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells.	BCR
33478278	10.1080/10428194.2021.1872074	2021	<i>BCR-ABL1</i> kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.	BCR
33485429	10.1016/j.clml.2020.08.011	2021	Philadelphia-Like Acute Lymphoblastic Leukemia: A Systematic Review.	BCR
33506273	10.1007/s00520-021-06016-z	2021	Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.	BCR
33513604	10.1182/blood.2020008835	2021	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.	BCR
33531346	10.1073/pnas.2016553118	2021	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.	BCR
33538150	10.3324/haematol.2020.260935	2021	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.	BCR
33542970	10.1200/PO.20.00360	2021	Acquired CARD11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma.	BCR
33554816	10.19746/j.cnki.issn.1009-2137.2021.01.028	2021	[Characteristic of 8p11 Myeloproliferative Syndrome with Rare Phenotype].	BCR
33560402	10.1182/bloodadvances.2020003768	2021	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.	BCR
33570628	10.1182/bloodadvances.2020001665	2021	Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.	BCR
33570732	10.1007/s12185-021-03094-x	2021	Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
33591648	10.1002/brb3.2061	2021	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).	BCR
33597098	10.1016/j.clml.2020.12.025	2021	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome.	BCR
33616915	10.1002/cncr.33347	2021	Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study.	BCR
33632667	10.1016/j.clml.2021.01.020	2021	Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia.	BCR
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	BCR
33646306	10.1182/bloodadvances.2020001844	2021	Genome-wide interference of ZNF423 with B-lineage transcriptional circuitries in acute lymphoblastic leukemia.	BCR
33648418	10.1080/10428194.2021.1885656	2021	Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.	BCR
33653205	10.1080/10428194.2021.1889536	2021	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.	BCR
33653209	10.1080/08880018.2020.1843577	2021	Intracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patient.	BCR
33672947	10.3390/biology10020152	2021	HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases.	BCR
33674940	10.1007/s00277-021-04483-2	2021	Very rare lineage switch from acute myeloid leukemia with BCR-ABL1 to B-lymphoblastic leukemia.	BCR
33684941	10.1182/blood.2020010438	2021	Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation.	BCR
33688166	10.2147/DDDT.S250823	2021	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.	BCR
33722147	10.1080/10428194.2021.1901094	2021	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.	BCR
33725318	10.1007/s12185-021-03116-8	2021	Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.	BCR
33728464	10.1182/blood.2020009855	2021	Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma.	BCR
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	BCR
33752626	10.1186/s12885-021-08015-z	2021	Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing.	BCR
33757770	10.1016/j.clml.2021.01.017	2021	Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.	BCR
33758275	10.1038/s41598-021-86021-8	2021	Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines.	BCR
33762010	10.1186/s13256-021-02771-z	2021	Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.	BCR
33762097	10.1016/j.beha.2021.101242	2021	Have any strategies in Ph-like ALL been shown to be effective?	BCR
33768841	10.1002/ccr3.3770	2021	High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib.	BCR
33774681	10.1007/s00277-021-04504-0	2021	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.	BCR
33781217	10.1186/s12885-020-07781-6	2021	Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.	BCR
33781551	10.1016/j.bulcan.2021.02.004	2021	COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE).	BCR
33786735	10.1007/s10815-021-02169-2	2021	Disease-inducing potential of two leukemic cell lines in a xenografting model.	BCR
33788182	10.1007/s40265-021-01507-z	2021	Ocular Toxicity of Targeted Anticancer Agents.	BCR
33808300	10.3390/curroncol28020131	2021	Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario.	BCR
33814500	10.2169/internalmedicine.7066-21	2021	BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy.	BCR
33823073	10.1002/cncr.33539	2021	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.	BCR
33851691	10.1358/dot.2021.57.4.3264113	2021	Tirabrutinib hydrochloride for B-cell lymphomas.	BCR
33853871	10.1128/mSphere.00093-21	2021	B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition.	BCR
33860589	10.1111/petr.14024	2021	Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome-like Relapsed/Refractory acute lymphoblastic leukemia.	BCR
33878293	10.1016/j.molcel.2021.03.043	2021	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.	BCR
33890726	10.1002/cjp2.211	2021	CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.	BCR
33895809	10.1182/blood.2020010144	2021	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.	BCR
33896586	10.1016/j.bulcan.2021.01.014	2021	[Richter Syndrome: Diagnostic and Therapeutic Management].	BCR
33906825	10.1016/j.clml.2021.03.007	2021	IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.	BCR
33907977	10.1007/s12185-021-03156-0	2021	Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.	BCR
33912159	10.3389/fimmu.2021.627602	2021	The <i>Traf2</i>DNx<i>BCL2-tg</i> Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart.	BCR
33921415	10.3390/cancers13081837	2021	Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.	BCR
33941506	10.1016/j.clml.2021.03.008	2021	Outcomes of Adolescent Patients with Acute Lymphoblastic Leukemia: Long-term Follow-up of 335 Patients.	BCR
33942128	10.1007/s00277-021-04507-x	2021	Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.	BCR
33944660	10.1080/10428194.2021.1894652	2021	Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.	BCR
33949040	10.1111/cas.14939	2021	RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.	BCR
33950935	10.1097/MD.0000000000025579	2021	The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies: A case report.	BCR
33988307	10.1111/ijlh.13580	2021	Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.	BCR
33990705	10.1038/s41379-021-00817-7	2021	Myeloid/lymphoid neoplasms with FLT3 rearrangement.	BCR
33991360	10.1002/ajh.26238	2021	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.	BCR
33993837	10.1080/10428194.2021.1919657	2021	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.	BCR
33999145	10.1182/bloodadvances.2020003566	2021	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.	BCR
34000704	10.1016/j.bioorg.2021.104968	2021	Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.	BCR
34014290	10.1182/blood.2021011420	2021	Basophilic myeloblasts: a clue for CML blast phase.	BCR
34027795	10.1080/10428194.2021.1929964	2021	The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.	BCR
34038034	10.1111/ped.14474	2021	Suspected chronic myeloid leukemia-like BCR-ABL1-positive acute lymphoblastic leukemia.	BCR
34048072	10.1002/ajh.26253	2021	Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.	BCR
34049715	10.1016/j.pathol.2021.02.013	2021	Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis.	BCR
34052176	10.1016/j.clml.2021.04.005	2021	Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.	BCR
34062932	10.3390/genes12050687	2021	Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.	BCR
34078586	10.1016/j.clml.2021.04.014	2021	Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events.	BCR
34102636	10.1159/000516593	2021	Durable Molecular Remission in an Elderly Patient Affected by Relapsed Ph&apos;+ Acute Lymphoblastic Leukemia with T315I and Concomitant p190 and p210 Expression Achieved by Inotuzumab and Ponatinib.	BCR
34106613	10.1097/MD.0000000000025786	2021	Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.	BCR
34106877	10.18632/aging.203116	2021	Identification of a nomogram based on an 8-lncRNA signature as a novel diagnostic biomarker for childhood acute lymphoblastic leukemia.	BCR
34110462	10.1007/s00277-020-04357-z	2021	Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1<sup>T315I</sup> and BCR-ABL1<sup>T315I-E255K</sup>.	BCR
34115047	10.1097/MD.0000000000026323	2021	Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.	BCR
34118580	10.1016/j.anndiagpath.2021.151767	2021	From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.	BCR
34120550	10.1080/14656566.2021.1941864	2021	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.	BCR
34130278	10.1159/000516003	2021	Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.	BCR
34157051	10.1371/journal.pone.0251719	2021	Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).	BCR
34158358	10.1158/1078-0432.CCR-20-5039	2021	SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma.	BCR
34158825	10.3332/ecancer.2021.1221	2021	T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.	BCR
34159401	10.1007/s00277-021-04574-0	2021	Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.	BCR
34160140	10.1002/adbi.202100220	2021	Functional Phenotype Flow Cytometry: On Chip Sorting of Individual Cells According to Responses to Stimuli.	BCR
34162990	10.1038/s41598-021-92647-5	2021	A microfluidic device enabling drug resistance analysis of leukemia cells via coupled dielectrophoretic detection and impedimetric counting.	BCR
34172894	10.1038/s41375-021-01277-3	2021	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.	BCR
34177947	10.3389/fimmu.2021.689472	2021	Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.	BCR
34189859	10.1002/cam4.4087	2021	Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.	BCR
34190698	10.22034/iji.2021.84496.1661	2021	Distinguishing Isolated Lymphoid Extramedullary Blast Crisis and Secondary Non-Hodgkin Lymphoma in Chronic Myelogenous Leukemia: a Case Report and Review of the Literature.	BCR
34195068	10.3389/fonc.2021.608238	2021	Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma.	BCR
34203891	10.3390/ijms22126411	2021	Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment.	BCR
34210682	10.1158/1078-0432.CCR-21-0553	2021	Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.	BCR
34217275	10.1186/s12920-021-01023-9	2021	Hypodiploidy in a pediatric patient of T-cell acute lymphoblastic leukemia: a case report.	BCR
34248965	10.3389/fimmu.2021.681984	2021	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.	BCR
34250504	10.1158/2643-3230.BCD-20-0229	2021	Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.	BCR
34251066	10.1002/jcla.23583	2021	Correlation analysis of long non-coding RNA TUG1 with disease risk, clinical characteristics, treatment response, and survival profiles of adult Ph<sup>-</sup> Acute lymphoblastic leukemia.	BCR
34254886	10.1080/10428194.2021.1950709	2021	COVID-19 in chronic myeloid leukemia patients in Latin America.	BCR
34263144	10.1097/HS9.0000000000000620	2021	The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.	BCR
34264564	10.20892/j.issn.2095-3941.2020.0291	2021	SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.	BCR
34266412	10.1186/s12885-021-08545-6	2021	DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database.	BCR
34314938	10.1016/j.bmc.2021.116275	2021	Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.	BCR
34320160	10.1182/blood.2020006784	2021	Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.	BCR
34323286	10.1002/eji.202048968	2021	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.	BCR
34324199	10.1002/eji.202149235	2021	Heterogeneity of germinal center B cells: New insights from single-cell studies.	BCR
34325057	10.1016/j.jmoldx.2021.07.008	2021	Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.	BCR
34325192	10.1016/j.leukres.2021.106647	2021	The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
34326740	10.1159/000516270	2021	P190 <sup><i>BCR-ABL1</i></sup> in a Patient with Philadelphia Chromosome Positive T-Cell Acute Lymphoblastic Leukemia: A Rare Case Report and Review of Literature.	BCR
34335584	10.3389/fimmu.2021.683597	2021	Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models.	BCR
34340673	10.1186/s12885-021-08635-5	2021	Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia.	BCR
34348305	10.1159/000518280	2021	Cytogenetic and Fluorescence in situ Hybridization Profile of Pediatric Acute Lymphoblastic Leukemia in a University Hospital in South India.	BCR
34371436	10.1016/j.leukres.2021.106683	2021	Proposal and clinical application of molecular genetic risk scoring system, MRplus, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.	BCR
34371731	10.3390/pharmaceutics13071040	2021	mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma.	BCR
34399819	10.1186/s40170-021-00263-8	2021	Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.	BCR
34400115	10.1016/j.clml.2021.06.026	2021	Long-Term Outcome of Philadelphia Chromosome Positive Leukemia From Eastern Indian Subcontinent: An Experience in the Era of Tyrosine Kinase Inhibitor (TKI) Therapy.	BCR
34402088	10.1002/hon.2913	2021	Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.	BCR
34403880	10.1016/j.neo.2021.07.009	2021	Oncogene-independent resistance in Philadelphia chromosome - positive (Ph<sup>+</sup>) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway.	BCR
34404682	10.1158/1055-9965.EPI-21-0423	2021	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software.	BCR
34405773	10.1080/10428194.2021.1966787	2021	Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
34406363	10.1084/jem.20202280	2021	Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.	BCR
34406581	10.1007/s12185-021-03186-8	2021	Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.	BCR
34417955	10.1007/s11899-021-00648-y	2021	Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses.	BCR
34477034	10.1080/10428194.2021.1955878	2021	The diagnostic profile of rare acute myelomegakaryoblastic leukemia.	BCR
34477813	10.1182/bloodadvances.2021004430	2021	IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.	BCR
34492682	10.1182/bloodadvances.2021004813	2021	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.	BCR
34497196	10.11406/rinketsu.62.1094	2021	[B cell acute lymphoblastic leukemia therapy: an up to date overview].	BCR
34504101	10.1038/s41467-021-25622-3	2021	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.	BCR
34511174	10.7499/j.issn.1008-8830.2105004	2021	Clinical features and prognosis of children with acute leukemias of ambiguous lineage under different diagnostic criteria.	BCR
34542753	10.1007/s10517-021-05268-3	2021	Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.	BCR
34551378	10.1016/j.cancergen.2021.09.001	2021	A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review.	BCR
34573335	10.3390/genes12091355	2021	Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.	BCR
34591424	10.32471/exp-oncology.2312-8852.vol-43-no-3.16548	2021	Evaluation of serum levels of selected cytokine receptors in adult B-cell precursor acute lymphoblastic leukemia and their association with prognostic factors and survival.	BCR
34625105	10.1186/s13256-021-03060-5	2021	Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report.	BCR
34625709	10.1038/s41388-021-02025-8	2021	Calcium-dependent signalling in B-cell lymphomas.	BCR
34626353	10.1007/978-3-030-78311-2_2	2021	Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma.	BCR
34653294	10.1111/cas.15164	2021	C/EBPβ induces B-cell acute lymphoblastic leukemia and cooperates with BLNK mutations.	BCR
34655194	10.7754/Clin.Lab.2021.210122	2021	IL-10 as an Indicator for Predicting Clinical Progression in Acute Lymphoblastic Leukemia Patients.	BCR
34681663	10.3390/ijms222011004	2021	Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.	BCR
34711820	10.1038/s41467-021-26407-4	2021	Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy.	BCR
34722279	10.3389/fonc.2021.733848	2021	Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.	BCR
34733777	10.3389/fonc.2021.701604	2021	Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study.	BCR
34737376	10.1038/s41598-021-00950-y	2021	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.	BCR
34763718	10.1186/s13046-021-02159-3	2021	ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.	BCR
34778802	10.1158/2643-3230.BCD-21-0063	2021	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.	BCR
34805008	10.4322/acr.2021.339	2021	Myeloid sarcoma: an uncommon presentation of myeloid neoplasms; a case series of 4 rare cases reported in a tertiary care institute.	BCR
34824268	10.1038/s41467-021-27232-5	2021	Single-cell analysis identifies dynamic gene expression networks that govern B cell development and transformation.	BCR
34830980	10.3390/cancers13225827	2021	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions.	BCR
34865703	10.1016/j.beha.2021.101331	2021	Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?	BCR
34884478	10.3390/ijms222312673	2021	BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.	BCR
34940123	10.3390/cimb43030149	2021	Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.	BCR
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	BCR
34993136	10.3389/fonc.2021.771669	2021	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.	BCR
35015676	10.1158/2643-3230.BCD-21-0131	2021	Epigenetic Rewiring of BCR Signaling as a Novel Mechanism of Ibrutinib Resistance in ABC-DLBCL.	BCR
35028611	10.1016/j.xcrm.2021.100470	2021	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system.	BCR
35158373	10.1182/hematology.2021000224	2021	MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	BCR
35186368	10.46234/ccdcw2021.269	2021	The Incidence of Lymphoma in Beijing: Comparing Results from MIS-CASS (2019) and Beijing Cancer Registry (2017).	BCR
35528192	10.1158/2767-9764.crc-21-0022	2021	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.	BCR
31980503	10.1101/mcs.a004838	2020	Functional characterization of two rare BCR-FGFR1<sup>+</sup> leukemias.	BCR
32047189	10.1038/s41598-020-59101-4	2020	Role of Vitamins A and D in BCR-ABL Arf<sup>-/-</sup> Acute Lymphoblastic Leukemia.	BCR
32052899	10.1002/jcla.23241	2020	T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).	BCR
32058318	10.1016/j.cancergen.2020.01.051	2020	Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-microarray in high-risk Australian AIEOP-BFM B-cell acute lymphoblastic leukaemia cohort.	BCR
32077355	10.1080/10428194.2020.1728751	2020	Longitudinal clonal architecture of acute myeloid leukemia with <i>NPM1</i> driver insertion, early <i>TET2</i> mutations and secondary e6a2 <i>BCR-ABL1</i> rearrangement.	BCR
32078009	10.1007/s00277-020-03953-3	2020	Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.	BCR
32083012	10.3389/fonc.2020.00067	2020	B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.	BCR
32090646	10.1080/10428194.2020.1713317	2020	Diffuse large B-cell lymphoma with low <sup>18</sup>F-fluorodeoxyglucose avidity features silent B-cell receptor signaling.	BCR
32107574	10.1007/s00277-020-03949-z	2020	T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.	BCR
32111748	10.21873/invivo.11802	2020	Targeting BCL-2 as a Therapeutic Strategy for Primary <i><sup>p210</sup>BCR-ABL1</i>-positive B-ALL Cells.	BCR
32122205	10.1080/10428194.2020.1734593	2020	Evidence of <i>BCR-ABL1</i>-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML).	BCR
32122281	10.1080/16078454.2020.1735670	2020	WT1 overexpression predicted good outcomes in adult B-cell acute lymphoblastic leukemia patients receiving chemotherapy.	BCR
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.	BCR
32146103	10.1016/j.clml.2019.12.019	2020	Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI.	BCR
32146105	10.1016/j.clml.2019.09.606	2020	Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value-A Multicenter Study From South India.	BCR
32147612	10.11406/rinketsu.61.128	2020	[Mediastinal abscess due to Aspergillus in a patient with atypical chronic myeloid leukemia, BCR-ABL1-negative].	BCR
32150610	10.1182/bloodadvances.2019001008	2020	The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia.	BCR
32154668	10.1002/cam4.2946	2020	Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.	BCR
32154977	10.1111/vco.12588	2020	Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog.	BCR
32161170	10.1128/JVI.02123-19	2020	Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.	BCR
32163558	10.1182/blood.2019004674	2020	Sugar-coated BCR kept during FL clonal evolution.	BCR
32168755	10.3390/cancers12030650	2020	Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment.	BCR
32179412	10.1016/j.bcmd.2020.102420	2020	Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.	BCR
32191635	10.1172/JCI134424	2020	Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.	BCR
32192770	10.1016/j.bbrc.2020.03.006	2020	A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton's tyrosine kinase and its drug-resistant variants.	BCR
32192976	10.1016/j.clml.2020.02.004	2020	Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS).	BCR
32194860	10.7150/thno.41362	2020	PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.	BCR
32199764	10.1016/j.clml.2020.01.008	2020	The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.	BCR
32201514	10.7150/jca.39083	2020	A novel classification based on B-cell receptor signal gene expression correlates with prognosis in primary breast diffuse large B-cell lymphoma.	BCR
32209331	10.1016/j.clml.2020.01.009	2020	Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.	BCR
32210016	10.3390/ijms21062206	2020	VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.	BCR
32219444	10.1182/blood.2019001417	2020	Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.	BCR
32235787	10.3390/ijms21062193	2020	The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.	BCR
32237084	10.1111/bjh.16627	2020	Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.	BCR
32238402	10.1101/mcs.a004937	2020	The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and <i>ZBTB20-JAK2</i> gene fusion presenting as B-lymphoblastic leukemia.	BCR
32272636	10.3390/cancers12040894	2020	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.	BCR
32291235	10.1016/j.clml.2020.02.013	2020	Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.	BCR
32311856	10.3343/alm.2020.40.5.417	2020	A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma.	BCR
32319365	10.19746/j.cnki.issn.1009-2137.2020.02.003	2020	[Epidemidogical Analysis of 982 Hospitalized Cases of Childhood Acute Lymphoblastic Leukemia].	BCR
32319419	10.19746/j.cnki.issn.1009-2137.2020.02.057	2020	[Research Progress on Pathogenic Genes of Ph-like Acute Lymphoblastic Leukemia--Review].	BCR
32330662	10.1016/j.anndiagpath.2020.151514	2020	From the archives of MD Anderson Cancer Center: BCR-ABL1-like B acute lymphoblastic leukemia with IGH/EPOR fusion.	BCR
32332702	10.1038/s41408-020-0308-3	2020	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.	BCR
32341085	10.26508/lsa.202000700	2020	Immunoglobulin expression in the endoplasmic reticulum shapes the metabolic fitness of B lymphocytes.	BCR
32342278	10.1007/s13577-020-00367-1	2020	MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy.	BCR
32352166	10.1111/bjh.16718	2020	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.	BCR
32362606	10.4103/jcrt.JCRT_137_17	2020	Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study.	BCR
32368831	10.1002/gcc.22858	2020	Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16.	BCR
32370190	10.3390/cancers12051143	2020	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.	BCR
32376649	10.4049/jimmunol.2000172	2020	Rapid Death of Follicular B Cells and Burkitt Lymphoma Cells Effectuated by Xbp1s.	BCR
32378810	10.1002/cam4.3099	2020	High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.	BCR
32384445	10.1097/MD.0000000000019962	2020	Occurrence of lymphoplasmacytic lymphoma in a chronic myeloid leukemia patient following long-term treatment with tyrosine kinase inhibitors: A case report.	BCR
32404891	10.1038/s41408-020-0323-4	2020	Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century.	BCR
32424289	10.1038/s41467-020-16375-6	2020	Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma.	BCR
32445026	10.1007/s11899-020-00591-4	2020	Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.	BCR
32452280	10.1080/10428194.2020.1768380	2020	Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes.	BCR
32453841	10.1182/bloodadvances.2020001466	2020	Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.	BCR
32455989	10.3390/cancers12051328	2020	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.	BCR
32457305	10.1038/s41408-020-0329-y	2020	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.	BCR
32481267	10.1097/MD.0000000000020009	2020	Observation of the molecular genetics among children with acute lymphoblastic leukemia: A retrospective study based on the SEER database.	BCR
32481736	10.3390/cancers12061396	2020	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.	BCR
32503572	10.1186/s13045-020-00905-2	2020	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.	BCR
32505444	10.1016/j.jiac.2020.05.001	2020	Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia.	BCR
32508181	10.1080/10428194.2020.1762876	2020	Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study.	BCR
32508223	10.1080/10428194.2020.1772476	2020	Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 <i>BCR-ABL1</i> transcripts in chronic myeloid leukemia.	BCR
32510610	10.1002/hon.2761	2020	On point in primary CNS lymphoma.	BCR
32552902	10.1186/s13045-020-00912-3	2020	Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.	BCR
32558932	10.1002/lipd.12254	2020	Low-Density Lipoproteins, High-Density Lipoproteins (HDL), and HDL-Associated Proteins Differentially Modulate Chronic Myelogenous Leukemia Cell Viability.	BCR
32565969	10.3892/ol.2020.11583	2020	Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments.	BCR
32571113	10.1080/10428194.2020.1775203	2020	Chronic myelogenous leukemia presenting as central retinal vein occlusion.	BCR
32581241	10.1038/s41467-020-16927-w	2020	Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
32585766	10.1002/1878-0261.12753	2020	Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.	BCR
32594584	10.1111/petr.13728	2020	The impact of donor full-length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT.	BCR
32611574	10.3324/haematol.2020.252916	2020	ABL-class fusion positive acute lymphoblastic leukemia: can targeting ABL cure ALL?	BCR
32620617	10.21873/anticanres.14367	2020	Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.	BCR
32653779	10.1016/j.canep.2020.101772	2020	Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases.	BCR
32654575	10.1080/10428194.2020.1791856	2020	Platelet function in patients with chronic myeloid leukemia treated with asciminib.	BCR
32659728	10.1016/j.advms.2020.06.002	2020	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.	BCR
32662346	10.1080/10428194.2020.1783444	2020	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.	BCR
32672489	10.1080/10428194.2020.1786556	2020	No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.	BCR
32681657	10.1111/cyt.12890	2020	Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia.	BCR
32691208	10.1007/s11060-020-03580-y	2020	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.	BCR
32694049	10.1016/j.clml.2020.05.003	2020	De Novo CD5<sup>+</sup> Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances.	BCR
32696696	10.1080/10428194.2020.1797008	2020	Clonal evolution with acquisition of <i>BCR-ABL1</i> in refractory acute myeloid leukemia post therapy with FLT3-inhibitor.	BCR
32700989	10.1080/10428194.2020.1795160	2020	Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia.	BCR
32702393	10.1016/j.exphem.2020.07.005	2020	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells.	BCR
32768385	10.1016/j.clml.2020.07.004	2020	Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia.	BCR
32784334	10.1097/CM9.0000000000000999	2020	TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia.	BCR
32803312	10.1007/s00277-020-04212-1	2020	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.	BCR
32810963	10.3760/cma.j.issn.0253-2727.2020.07.006	2020	[Prognostic analysis of allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in complete remission in the era of tyrosine kinase inhibitors].	BCR
32812094	10.1007/s10561-020-09855-y	2020	Screening for pre-leukemia TEL-AML1 chromosomal translocation in banked cord blood units: cord blood bank perspective.	BCR
32812190	10.1007/s12185-020-02965-z	2020	JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).	BCR
32826247		2020	Identification of Two Novel Truncated Transcripts of Janus Kinase 2 Gene.	BCR
32829325	10.1159/000509639	2020	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.	BCR
32852239	10.1080/10428194.2020.1811272	2020	Prognostic value of MRD monitoring based on <i>BCR-ABL1</i> copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia.	BCR
32853380	10.1182/blood.2020006326	2020	Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.	BCR
32856506	10.1080/10428194.2020.1811269	2020	Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells.	BCR
32862848	10.1016/S2152-2650(20)30477-8	2020	Update on CML-Like Disorders.	BCR
32862868	10.1016/S2152-2650(20)30460-2	2020	Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care.	BCR
32902203	10.1002/cnr2.1290	2020	Recurrent genetic abnormalities detected by FISH in adult B ALL and association with hematological parameters.	BCR
32911643	10.3390/ijms21186556	2020	Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.	BCR
32913188	10.1038/s41419-020-02949-1	2020	A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1<sup>-</sup> pre-B-ALL.	BCR
32924711	10.1080/10428194.2020.1817444	2020	Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?	BCR
32946981	10.1016/j.exphem.2020.09.184	2020	Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature.	BCR
32955830	10.23736/S0026-4806.20.07031-7	2020	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.	BCR
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenström macroglobulinemia.	BCR
32974613	10.1158/0008-5472.BCD-19-0039	2020	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions.	BCR
32983140	10.3389/fimmu.2020.01995	2020	Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia.	BCR
33004416	10.1101/gad.340216.120	2020	EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.	BCR
33004801	10.1038/s41419-020-03035-2	2020	BAFF-driven NLRP3 inflammasome activation in B cells.	BCR
33005100	10.1186/s12935-020-01518-y	2020	Ibrutinib in B-cell lymphoma: single fighter might be enough?	BCR
33016157	10.1080/14737140.2020.1832890	2020	Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.	BCR
33020271	10.1073/pnas.2007946117	2020	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	BCR
33050534	10.3390/cancers12102913	2020	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.	BCR
33054045	10.3324/haematol.2018.207019	2020	BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy.	BCR
33067949	10.19746/j.cnki.issn.1009-2137.2020.05.017	2020	[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].	BCR
33091668	10.1016/j.bioorg.2020.104377	2020	HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.	BCR
33093447	10.1038/s41467-020-18998-1	2020	Targeting N-myristoylation for therapy of B-cell lymphomas.	BCR
33093947	10.12688/f1000research.22318.1	2020	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.	BCR
33113607	10.3760/cma.j.issn.0253-2727.2020.09.008	2020	[Diagnosis of adult Philadelphia chromosome-like acute lymphoblastic leukemia by fluorescence in situ hybridization].	BCR
33122918	10.2147/OTT.S275334	2020	Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.	BCR
33126303	10.1097/MD.0000000000022490	2020	A case report of lineage switch from T-cell acute leukemia to B-cell acute leukemia.	BCR
33126344	10.1097/MD.0000000000022904	2020	Clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia.	BCR
33126415	10.3390/ijms21218006	2020	Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.	BCR
33134182	10.3389/fonc.2020.592205	2020	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?	BCR
33149299	10.1038/s41586-020-2884-6	2020	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells.	BCR
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	BCR
33157925	10.1097/MD.0000000000022791	2020	Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report.	BCR
33157999	10.1097/MD.0000000000023154	2020	AML, ALL, and CML classification and diagnosis based on bone marrow cell morphology combined with convolutional neural network: A STARD compliant diagnosis research.	BCR
33162520	10.11406/rinketsu.61.1227	2020	[Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].	BCR
33164984	10.1172/JCI140797	2020	Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.	BCR
33194070		2020	Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.	BCR
33194762	10.3389/fonc.2020.595832	2020	ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.	BCR
33206758	10.6061/clinics/2020/e2011	2020	Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.	BCR
33207194	10.1016/j.celrep.2020.108403	2020	Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells.	BCR
33214594	10.1038/s41598-020-75860-6	2020	Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.	BCR
33226961	10.18632/aging.104136	2020	Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia.	BCR
33230098	10.1038/s41408-020-00388-x	2020	Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.	BCR
33242441	10.1016/S2352-3026(20)30369-0	2020	Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia?	BCR
33256901	10.1053/j.seminhematol.2020.09.001	2020	New approaches to the treatment of older adults with acute lymphoblastic leukemia.	BCR
33277547	10.1038/s41598-020-78024-8	2020	Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia.	BCR
33282736	10.3389/fonc.2020.580364	2020	Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.	BCR
33283707	10.19746/j.cnki.issn.1009-2137.2020.06.008	2020	[Effect of the Risk Factors for Treatment-Related Death in Children with Acute Lymphoblastic Leukemia].	BCR
33283718	10.19746/j.cnki.issn.1009-2137.2020.06.019	2020	[Clinical Efficacy of ALL-2005 and ALL-2009 Regimen and Factors Influencing Prognosis of Newly Diagnosed ALL Patients Aged between 10-18 Years Old].	BCR
33322625	10.3390/cancers12123738	2020	Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients.	BCR
33323828	10.1097/CM9.0000000000001294	2020	R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms.	BCR
33324393	10.3389/fimmu.2020.560244	2020	Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.	BCR
33338050	10.1371/journal.pone.0243657	2020	Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis.	BCR
33343851	10.1155/2020/6648574	2020	IoMT-Based Automated Detection and Classification of Leukemia Using Deep Learning.	BCR
33356083	10.26444/aaem/115393	2020	Use of microarrays and MLPA for integrating diagnostics and personalizing treatment - Case report of a patient with Ph-like acute B-cell lymphoblastic leukemia.	BCR
33363034	10.3389/fonc.2020.604685	2020	Role of Specific B-Cell Receptor Antigens in Lymphomagenesis.	BCR
33419251	10.3390/ijms21249724	2020	Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.	BCR
33445849	10.3760/cma.j.issn.0253-2727.2020.12.008	2020	[Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].	BCR
33552960	10.3389/fonc.2020.584149	2020	Case Report: A Case With Philadelphia Chromosome Positive T-Cell Lymphoblastic Lymphoma and a Review of Literature.	BCR
34661138	10.1158/2643-3249.BCD-20-0078	2020	<i>MEF2D</i> Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL.	BCR
34661142	10.1158/2643-3230.BCD-19-0080	2020	Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.	BCR
32568493		2019	[Coexistence of mycosis fungoides and essential thrombocythemia with JAK2V617F].	BCR
28540759	10.1080/10428194.2017.1320711	2018	Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.	BCR
26607903	10.1016/j.canlet.2015.11.020	2016	Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.	BCR
25769542	10.3324/haematol.2014.117424	2015	Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.	BCR
24856998		2014	[Clinical characteristics of childhood leukemia with EVI1 gene and BCR/ABL gene co-expression].	BCR
23171834	10.1159/000341289	2013	A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.	BCR
23289360	10.3109/10428194.2012.762649	2013	The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.	BCR
23974192	10.1182/blood-2012-10-462358	2013	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.	BCR
22231445	10.1038/onc.2011.604	2012	STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.	BCR
22233112	10.3109/10428194.2012.656104	2012	BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.	BCR
22384256	10.1371/journal.pone.0032451	2012	Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.	BCR
22591684	10.1016/j.leukres.2012.03.020	2012	Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.	BCR
22593461		2012	T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.	BCR
21504383	10.3109/10428194.2011.559670	2011	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?	BCR
21960589	10.1182/blood-2011-07-366542	2011	Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.	BCR
20038234	10.3109/10428190903503446	2010	Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.	BCR
20141430	10.3109/10428190903586326	2010	Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia.	BCR
19557636	10.1080/10428190902930496	2009	New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.	BCR
19608682	10.3324/haematol.2009.010900	2009	An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia.	BCR
18538733	10.1016/j.ccr.2008.04.018	2008	Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.	BCR
18617057	10.1016/j.cancergencyto.2008.04.003	2008	Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution.	BCR
18704194	10.1172/JCI33337	2008	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.	BCR
18784740	10.1038/leu.2008.242	2008	Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.	BCR
18809762	10.1182/blood-2008-04-148791	2008	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.	BCR
17638851	10.1182/blood-2007-01-068122	2007	Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells.	BCR
17762503	10.1097/MPH.0b013e3180f61bcf	2007	Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukemia (ALL) patients reflects ethnic differences in molecular genetics of ALL.	BCR
17768128	10.3324/haematol.11341	2007	Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sézary syndrome.	BCR
16966279	10.1080/10428190600709572	2006	Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.	BCR
15716990	10.1038/sj.leu.2403629	2005	Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia.	BCR
16116902		2005	[Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].	BCR
14993251	10.1084/jem.20031637	2004	The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells.	BCR
14534537	10.1038/sj.onc.1206747	2003	Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.	BCR
12408765		2002	Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.	BCR
11069024	10.1038/sj.leu.2401923	2000	Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins.	BCR
10194128	10.3109/10428199909093732	1999	CRKL binding to BCR-ABL and BCR-ABL transformation.	BCR
2193202		1990	A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
2407300		1990	Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.	BCR
